Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
no in this context it is things like funding civil society organisations, organisations that support micro finance for small businesses, esp. those run by women etc...
Tough on economic migration tough on the cause of economic migration is my favoured policy. In terms of addressing causes, lots of use of soft power to reduce conflict and warfare and increase democracy, civil society, stability. Plus fair trade to encourage economic growth in poorer countries. Plus more support for neighbour countries taking in migrants after conflict/war.
timbo - what is your point about economic migrants? If the roles were reverse you would potentially do the same - i.e. go to the jursdiction where there was more chance of work, plus maybe you could speak some of the language and maybe you already had people you knew there. Migration is obviously a global social issue. Much of it occurs from regimes which have corrupt/unstable/ undemocratic gvmt and have practical problems living a comfortable live such as because they are run down economically or wartorn. If I lived in a place like that I would want to leave even if my life was not under immediate threat.
he is probably in for now given that he is somewhat positive. The constant reference to himself in the third person might suggest a disassociation or might just be a way to keep his brain free of an oversized ego.
roundhowe - on the 21st June update they did say they had got some way into the process with European manufacturers - I understood that the pace would pick up as/when orders in Europe required that - which may well have been a number of weeks ago given that the Bioserve situation suggests a need to up supply.
Quite agree, best test.
I admit to being naive. About the government. Its corrupt machinations and incompetence have probably both been negative for the speed and extent of the LFT rollout. Also about the time it takes to get these things selling en-masse, especially for a small company.
So I will say my previous prediction of tenner by end of summer is now a very outside chance. But I also think that the sp as it is reflects a very rain cloudy view of what can be accomplished via the LFT both in terms of profits directly and in terms of elevating the whole future of Avacta diagnostics in LFT form and more generally.
It is just a matter of time - a few months perhaps - before we fill the boots of our 35m capacity which would be worth between 400-800 profit per year as things stand. I suspect also we will have at least an equally large capacity produced by MedUSA bringing us a similar amount of profit.
certainly big scope for upside surprises on these partnership deals. I think whilst its mostly kept confidential we will see it reflected in next few years in the financial results
Last year has been a salutory lesson. Seemingly messed around by Govmt validation processes which probably resulted in our test being delayed by many months and Govmt may not be interested in the end due to corruption. Lower margins as well. But all of this is more than priced in. And there is lots of potential still for upside. I have a good feeling we will be back over two quid as a minimum by end of August. Medusa will be excellent at selling and are probably going to be producing at volume. And I think we will start getting news of large contracts in Europe and perhaps rest of world too.
Of course they could make our test beinthelead. Notice also the answer to the que will it be affidx was not NO but effectively a definitely NOT NOW. If Govmt goes with Avct as one of the tests they purchase ODX could be making it in the autumn or winter.
If it doesn't come he will be pasting about Yorkshire tea
A broad partnership with Mologic to make LFTs with affimers seems to be very much on the cards as a minimum, low profit per test for Avacta in the deal but most probably great volumes.
Agree Ophidian on saliva, Killed off by the amazing sensitivity of the AN test and by the fact that AN architecture is going to be springboard for a whole new gen of tests - including a range that addresses diseases that were previously dismissed as too difficult and/or too uneconomic to address profitably
Bethell and Han**** had their vip lane and managed it through non-government communication. We know that is a set up specifically designed to allow fair play to be bypassed. And what we also know is that the words from government about supporting british diagnostics would have been backed by by proper substance had it not been for spivvery. I mean no minister in their right mind who didn't have fingers in the pie would sit around seeing companies like Mologic and Avacta get thwarted at numerous points by things like Porton Down, the incompetence and pointlessness of Condor, Falcon etc. There can be only one logical reason why they bend rules for chinese tests (home use authorisation exemption when not validated with relevant sample type and poor sensitivity) and yet sit by why obstructions are placed in the way of British.
I am always impatient. Always want to move on. But this is one of those shares that is too good potential wise. Sitting on hands. Will have to put up with the volatility and wait until its more fully valued. Not sure what level that will be - maybe if the drills finish off in the very good way they have gone it will get into the 20s. Sell something mediocre instead.
1.As far as I can see the Directive came into effect in Jan 2013.
2.It is the Directive itself that, in the light of scientific developments with affimers etc. brings a position that the use of animals in the creation of antibodies is no long be legally acceptable. This recommendation simply highlights the specific fact of this and is a mechanism to bring the attention of member states, scientists and companies et. to the fact. Indeed, according to this Recommendation it ought to have been stopped several years ago as other methods were already sufficiently mature.
3.Directives are binding not just on member states but become automatically part of member state law and are thus binding on all within each member state.
4.Recommendations have no legal force per se but are likely to be persuasive in a domestic Court and the ECJ and thus it would be legally and commercially risky not to follow the line of interpretation of the Directive that this Recommendation is putting forward.
5.In short its fab news for affimers and potentially other non-animal derived alternatives
Yes CO - it would be after we are swilling in cash (if all goes to plan). Pigster with automation and including shipping possibly nearly as cheap and with onshore advantages in terms of speed and potentially politics (buying British may well become a real thing rather than a thing politicians just pretend to be interested in). I was more interested in it for the seamless development, manufacturing knowhow and speed to market.
It can bring benefits of expertise to select between third parties when getting a test out. However, it also brings delays due to negotiations, legals, the backwards and forwards etc. Avct ultimately need high amounts of vertical integration if they are going to get test concept to actual test to on the market in the quickest possible time and maximise the advantages of affimers. That doesn't mean they need a grunt factory to produce 100s of millions of test but one that can produce a few million would not go amiss because it gives you a decent bulk of tests to sell almost from the off after validation/registration
ABd
Would not be surprised to see a few years of step changes in size and profiability for this company - via a mix of good organic growth and careful bolt on complementary acquisitions. Wouldn't want to hazard a guess on the sp after that as their are too many unknowns. But I would not be at all surprised if investors doubled their money from here.
Ray you are 7 months late responding to this thread with an obvious agenda...
We don't know how fast and at what scale the contracts will materialise. Things are generally taking longer when we expect. But let me put it a different way how many lfts do you think we will book for sale in total over the course of the pandemic? My answer would be somewhere upwards of a billion with a similar profit minimum in pounds terms. It could be months before the evidence fully points the market in that direction figures wise but when it does a fiver or even a tenner are the likely result.